• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

亚洲房颤患者接受口服抗凝剂预防卒中时发生胃肠道出血的风险

Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation.

作者信息

Diaz Alejandro Bimbo, Chow Jeremy, Hoo Fan Kee, Keong Gary Lee Chin, Venketasubramanian Narayanaswamy, Rey Nannette, Rogelio Gregorio, Mehta Radhika

机构信息

University of Santo Tomas Hospital, Manila, Philippines.

Asian Heart & Vascular Centre, Singapore, Singapore.

出版信息

Drugs Context. 2024 Aug 13;13. doi: 10.7573/dic.2024-5-5. eCollection 2024.

DOI:10.7573/dic.2024-5-5
PMID:39165614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11335362/
Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.

摘要

非维生素K拮抗剂口服抗凝药（NOACs）越来越多地用于心房颤动的卒中预防。在2023年亚太地区依度沙班推进患者护理会议上，专家们分享了关于在亚洲临床实践中使用NOACs预防心房颤动卒中时胃肠道出血的见解，在亚洲，NOACs因其良好的特性而获得广泛认可。不同NOACs的胃肠道出血风险各不相同，这凸显了对患者进行认真评估、选择合适剂量以及进行密切监测的重要性。与非亚洲患者相比，依度沙班在亚洲患者中呈现出胃肠道出血风险较低的特性，是一种可行的选择，这支持其继续在合适的患者中进行临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/4c5e14c748f6/DIC-2024-5-5_DIAZ_TS_190724-Figure_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/05061d90fbc2/DIC-2024-5-5_DIAZ_TS_190724-Figure_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/ab98051ffefe/DIC-2024-5-5_DIAZ_TS_190724-Figure_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/4603780f23f7/DIC-2024-5-5_DIAZ_TS_190724-Figure_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/c921f3e67408/DIC-2024-5-5_DIAZ_TS_190724-Figure_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/4c5e14c748f6/DIC-2024-5-5_DIAZ_TS_190724-Figure_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/05061d90fbc2/DIC-2024-5-5_DIAZ_TS_190724-Figure_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/ab98051ffefe/DIC-2024-5-5_DIAZ_TS_190724-Figure_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/4603780f23f7/DIC-2024-5-5_DIAZ_TS_190724-Figure_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/c921f3e67408/DIC-2024-5-5_DIAZ_TS_190724-Figure_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddde/11335362/4c5e14c748f6/DIC-2024-5-5_DIAZ_TS_190724-Figure_5.jpg

相似文献

1
Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation.亚洲房颤患者接受口服抗凝剂预防卒中时发生胃肠道出血的风险
Drugs Context. 2024 Aug 13;13. doi: 10.7573/dic.2024-5-5. eCollection 2024.
2
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.非维生素K拮抗剂口服抗凝药用于亚洲房颤患者的卒中预防：重新评估的时候了。
Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182. Epub 2014 Nov 26.
3
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.当代口服抗凝剂在亚洲非瓣膜性心房颤动患者中的疗效和安全性。
Stroke. 2019 Aug;50(8):2245-2249. doi: 10.1161/STROKEAHA.119.025536. Epub 2019 Jun 18.
4
The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.亚洲心房颤动患者中新型口服抗凝药与维生素 K 拮抗剂之间胃肠道出血风险的荟萃分析。
Int J Environ Res Public Health. 2020 Dec 27;18(1):137. doi: 10.3390/ijerph18010137.
5
Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.亚洲超高肾功能患者的非维生素 K 拮抗剂口服抗凝剂。
Stroke. 2019 Jun;50(6):1480-1489. doi: 10.1161/STROKEAHA.118.024264. Epub 2019 May 14.
6
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.非维生素K拮抗剂口服抗凝剂用于心房颤动和静脉血栓栓塞的有效性和安全性：一项系统评价和荟萃分析
Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28.
7
Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.亚洲房颤患者非维生素K拮抗剂口服抗凝药的超说明书用药剂量与临床结局
Heart Rhythm. 2020 Dec;17(12):2102-2110. doi: 10.1016/j.hrthm.2020.07.022. Epub 2020 Jul 20.
8
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.极低剂量与常规剂量非维生素K拮抗剂口服抗凝剂治疗出血风险增加的老年房颤患者的临床结局：一项全国性队列研究
Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):681-691. doi: 10.1093/ehjcvp/pvad058.
9
Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials.亚洲房颤患者中标准剂量与低剂量非维生素K拮抗剂口服抗凝药的比较：当代随机对照试验的荟萃分析
Heart Rhythm. 2016 Dec;13(12):2340-2347. doi: 10.1016/j.hrthm.2016.09.010. Epub 2016 Sep 8.
10
Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation.日本非瓣膜性心房颤动患者非维生素K拮抗剂口服抗凝剂治疗选择的特殊考量
Clin Cardiol. 2017 Feb;40(2):126-131. doi: 10.1002/clc.22596. Epub 2016 Oct 7.

引用本文的文献

1
Bibliometric Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACS) in the Prevention of Venous Thrombosis and Pulmonary Embolism.非维生素K拮抗剂口服抗凝剂（NOACs）预防静脉血栓形成和肺栓塞的文献计量分析
Drug Des Devel Ther. 2025 Apr 30;19:3589-3610. doi: 10.2147/DDDT.S505751. eCollection 2025.
2
Left atrial appendage occlusion in atrial fibrillation: shaping the future of stroke prevention.心房颤动中的左心耳封堵：塑造卒中预防的未来。
Future Cardiol. 2025 May;21(6):391-404. doi: 10.1080/14796678.2025.2484964. Epub 2025 Mar 26.

本文引用的文献

1
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program.艾多沙班用于心房颤动的处方模式及治疗结果：来自全球ETNA-AF项目的一年数据。
J Clin Med. 2023 Feb 27;12(5):1870. doi: 10.3390/jcm12051870.
2
Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms.非维生素 K 拮抗剂口服抗凝剂致胃肠道出血的分子机制研究
Int J Mol Sci. 2022 Nov 12;23(22):13955. doi: 10.3390/ijms232213955.
3
Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?
老年房颤患者的最佳抗凝治疗：哪种药物，哪种剂量？
Kardiol Pol. 2022;80(2):128-136. doi: 10.33963/KP.a2022.0046. Epub 2022 Feb 15.
4
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.直接口服抗凝药与华法林在心房颤动患者中的比较：按年龄和性别进行交互测试的随机临床试验的患者水平网络荟萃分析。
Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.
5
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation.亚太心律学会（APHRS）2017年房颤卒中预防共识指南2021年重点更新。
J Arrhythm. 2021 Nov 13;37(6):1389-1426. doi: 10.1002/joa3.12652. eCollection 2021 Dec.
6
Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.依度沙班在韩国和台湾地区心房颤动患者常规临床实践中的临床事件
J Clin Med. 2021 Nov 16;10(22):5337. doi: 10.3390/jcm10225337.
7
Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.韩国和中国台湾地区房颤患者使用依度沙班预防卒中的剂量相关因素：来自全球 ETNA-AF 项目的 1 年数据。
J Chin Med Assoc. 2021 May 1;84(5):485-490. doi: 10.1097/JCMA.0000000000000516.
8
Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.质子泵抑制剂联合治疗伴上消化道出血史的口服抗凝药物治疗的心房颤动患者。
Cardiovasc Drugs Ther. 2022 Aug;36(4):679-689. doi: 10.1007/s10557-021-07170-6. Epub 2021 Mar 17.
9
Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (≥85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study.非维生素 K 拮抗剂口服抗凝药在新诊断的心房颤动老年（≥85 岁）患者中的应用：一项全国性队列研究中预防卒中的临床实践和结局的改变。
Mayo Clin Proc. 2021 Jan;96(1):52-65. doi: 10.1016/j.mayocp.2020.08.042.
10
Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.非瓣膜性心房颤动患者使用依度沙班的上市后监测（ETNA-AF-日本）：一年安全性和有效性分析。
J Arrhythm. 2020 Mar 24;36(3):395-405. doi: 10.1002/joa3.12332. eCollection 2020 Jun.